Clinical Trials Logo

Clinical Trial Summary

Sepsis is a heterogeneous syndrome that is caused by the host imbalance immune response. At 1991, the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference developed a definition of sepsis. After more than 20 years, it was gradually developed in 2016 to the third edition of the guidelines for sepsis(Sepsis-3). Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. According to the National Health Insurance claims database of Taiwan, The incidence rate was 772.1/100,000 persons in 2012. From 2002 to 2012, the incidence of sepsis increased by 18.7%. The mortality of severe sepsis was 17.9%. However, has increased to 33% when developed to septic shock. Even in foreign studies, the intensive care unit mortality rate can reach 40%. Although sepsis was defined in 1991, after these years, the treatment of sepsis is still a goal that must be worked hard.

According to Sepsis-3, must first use the qSOFA (quick Sepsis Related Organ Failure Assessment) to assess whether the patient's blood pressure, respiratory rate, and state of consciousness meet more than two criteria, which is sepsis. If the SOFA score (Sequential Organ Failure Assessment) is further evaluated, with at least two of the following symptoms, including poor oxygenation in the lungs, hypotension or use of a vasopressor, thrombocytopenia, conscious change (Glasgow Coma Scale), bilirubin increase and creatinine rise or oligouria. If the patient must use a vasopressor to maintain a mean arterial pressure (MAP) of 65 mmHg and serum lactate more than 18 mg/dL, it is Septic shock. In clinical assessment, qSOFA (rapid sepsis-associated organ failure assessment) can also be used to assess blood pressure, respiratory rate, and state of consciousness to confirmed sepsis. According to the above assessment conditions, patients with sepsis are highly prone to respiratory failure during the disease process. In recent trials, about 40% to 85% of patients with sepsis must be need endotracheal intubation, showing the high intubation rate. Patients after intubation may cause lung injury due to improper ventilator settings (Ventilator-induced lung injury, VILI). And 10% to 25% will be combined with pneumonia caused by the ventilator (ventilator-associated pneumonia, VAP). Mortality can reach 20% to 33%. So if we can reduce septic patient's intubation rate then we can reduce the complication caused by the ventilator.

A high flow nasal cannula (HFNC) is a relatively new device for respiratory support. Patients received high-flow conditioned oxygen therapy through a nasal prong. A number of physiological effects have been described with HFNC: pharyngeal dead space washout, a positive expiratory pressure to reduce work of breathing, improve breathing synchronization. These benefits can reduce the intubation rate.

The benefit of the HFNC in septic patients is not very clear. By this prospective study to investigate the septic patients who have been admitted to the intensive care unit. The study method is to ask the patient whether they agree to participate in the trial after the patient is transferred to the intensive care unit. The patient will randomly assign the subjects to the general oxygen therapy and the HFNC group after signing the subject consent form. This study aimed to determine whether high-flow oxygen therapy immediately would reduce the need for intubation compared with standard oxygen therapy in sepsis patients.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04560842
Study type Interventional
Source Mackay Memorial Hospital
Contact Shuo Ping Tseng
Phone 886-989452824
Status Not yet recruiting
Phase N/A
Start date September 25, 2020
Completion date September 24, 2021

See also
  Status Clinical Trial Phase
Completed NCT04475081 - Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis Phase 3
Completed NCT03314831 - The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis
Completed NCT03371680 - Kinetics of Surfactant Proteins, Phosphatidylcholine and Body Water in Intensive Care Unit (ICU) N/A
Completed NCT00046072 - A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis Phase 2
Enrolling by invitation NCT05602584 - Effect of Immunophenotype on Prognosis of Sepsis
Completed NCT06338111 - Interventions Meant to Improve the Outcome of Critical Care Patients in the ED
Completed NCT04292431 - Leukocyte MOrphology and CORticosteroids Response in SEPtic Patients (MOCORSEP)
Recruiting NCT03472170 - Clinical Trial for Valuation of the Effectiveness of Lactoferrine in the Prevention of Sepsis in New Premature Born. Bimonitorization of the Antinflammatory Mechanisms, Antioxidants and the Intestinal Microbiote. N/A
Not yet recruiting NCT05382078 - Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
Recruiting NCT03956043 - Diagnostic Accuracy in Sepsis
Recruiting NCT05977153 - CT for Personalized Mechanical Ventilation N/A
Completed NCT00448968 - The Utility of Ischemia Modified Albumin (IMA) in Sepsis N/A
Completed NCT05246969 - Detecting Sepsis in Patients With Severe Subarachnoideal Hemorrhage
Recruiting NCT05261607 - Analysis of the Evolution of Mortality in an Intensive Care Unit
Recruiting NCT04203979 - Sepsis: From Syndrome to Personalized Care
Recruiting NCT03990467 - Observed Pharmacokinetic of Piperacillin/Tazobactam Compared to Amikacin in ICU N/A
Recruiting NCT05338359 - Metrology to Enable Rapid and Accurate Clinical Measurements in Acute Management of Sepsis
Completed NCT02562261 - Platelet REactivity in Sepsis Syndrome (PRESS)
Active, not recruiting NCT02643121 - Utility of Presepsin in Children Sepsis N/A
Completed NCT00142220 - The Benefit of Adding Fish Oil to the Nutrition of Critically Ill Patients Phase 4